Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LipocineSTU:2VT0 51 Forward PE Ratio is 0.00 as of Jul. 17, 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 51/100 and a GF Value™ of €3.27. The stock has 4 warning signs investors should review. Among 354 Biotechnology companies, Lipocine ranks worse than 282485.59% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Lipocine Forward PE Ratio Related Terms
Lipocine Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Lipocine's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine Forward PE Ratio Chart
Lipocine Annual Data
Trend
Forward PE Ratio
Lipocine Quarterly Data
Forward PE Ratio
STU:2VT0 vs NCEL, PTN, ALLR: Forward PE Ratio Comparison
For the Biotechnology subindustry, Lipocine's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Lipocine's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Lipocine (STU:2VT0) has a Forward PE Ratio of 0.00 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Lipocine and its competitors. According to the industry distribution chart, Lipocine ranks #999999 out of 354 companies in the Biotechnology industry.
Is Lipocine's Forward PE Ratio too high?
Lipocine's current Forward PE Ratio is 0.00. Based on the distribution chart, Lipocine ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lipocine has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Forward PE Ratio compare to NCEL and PTN?
According to the Biotechnology industry distribution chart, Lipocine ranks #999999 out of 354 companies for Forward PE Ratio. This places Lipocine in the lower half of its industry. The industry median Forward PE Ratio is 21.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Lipocine and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipocine's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Forward PE Ratio of 0.00. The stock's GF Value™ is €3.27, compared to a current price of €3.94 — trading 20.6% above its estimated fair value. The current Forward PE Ratio is 0.00. Lipocine's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Forward PE Ratio is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (STU:2VT0) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of €3.94 is trading 20.6% above its estimated GF Value™ of €3.27.
Key valuation signals for STU:2VT0:
Forward PE Ratio: 0.00
GF Value™: €3.27 vs. price of €3.94 (20.6% above fair value)
No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
51GF Score
Get the complete analysis for STU:2VT0
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2VT0 has been successfully added to your 
